Medical Developments International (MDI) has announced data from multiple European studies demonstrating the benefits of MDI’s Penthrox methoxyflurane inhaler for the treatment of pain from acute trauma.
Among the findings announced, Penthrox was shown to be superior to intravenous morphine, NSAIDS, paracetamol (acetaminophen), and ketoprofen in trauma settings; Penthrox successfully reduced pain in discolation injuries, resulting in less time spent in the emergency department; and health care professionals and patients were highly satisfied with the inhaler.
MDI CEO John Sharman commented, “We are delighted with the results of these recent European clinical trials demonstrating superiority of Penthrox over standard of care treatments (intravenous (IV) morphine, IV paracetamol, ketoprofen or NSAIDS) within the acute trauma setting. This reinforces the global potential for Penthrox as a simple, fast and effective non-opioid pain medication.”
MDI also announced the launch of Penthrox in Italy, which will trigger a $2 million milestone payment from Mundipharma in 2020. Mundipharm has the rights to Penthrox in most of Europe and in Australia.
Sharman said, “We are delighted to finally launch Penthrox in the important European market of Italy. There has been a number of clinical studies completed in preparation for the launch of Penthrox in Italy. In particular, a study of 272 trauma patients in 15 Italian emergency units (“MEDITA”), showed that Penthrox was superior to standard of sare, including opioids, for adult trauma pain patients in Italy. . . . Penthrox is now well placed to develop into a leading trauma pain medication in Italy and throughout Europe.”
Mundipharma Asset Lead Maya Marescotti added, “We are delighted to have launched Penthrox in Italy, to help provide fast and effective relief for adult patients experiencing trauma pain. We see this inhaled analgesic as an important medication for trauma patients here and throughout Europe and we look forward to our continued collaboration with MDI.”
Read the MDI press release on Penthrox study results.
Read the MDI press release on the Penthrox launch in Italy.
